OMER Omeros Corp
Omeros Corp (OMER) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.2% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Omeros Corp
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.
Sector
Healthcare
Industry
Biotechnology